We carried out a fine-mapping study in the HNF1B gene at 17q12 in two study populations and identified a second locus associated with prostate cancer risk, B26 kb centromeric to the first known locus (rs4430796); these loci are separated by a recombination hot spot. We confirmed the association with a SNP in the second locus (rs11649743) in five additional populations, with P ¼ 1.7 Â 10 À9 for an allelic test of the seven studies combined. The association at each SNP remained significant after adjustment for the other SNP.
We carried out a fine-mapping study in the HNF1B gene at 17q12 in two study populations and identified a second locus associated with prostate cancer risk, B26 kb centromeric to the first known locus (rs4430796); these loci are separated by a recombination hot spot. We confirmed the association with a SNP in the second locus (rs11649743) in five additional populations, with P ¼ 1.7 Â 10 À9 for an allelic test of the seven studies combined. The association at each SNP remained significant after adjustment for the other SNP.
A locus in the HNF1B gene at 17q12 was initially reported to be associated with prostate cancer risk in a genome-wide association study (GWAS) in Iceland 1 and was later replicated in two additional GWAS in the UK 2 and in the United States 3 , as well as in two confirmation studies from our group 4, 5 . We found several SNPs at 17q12, including rs4430796, to be strongly associated with prostate cancer risk in a population-based case-control study from Sweden (CAPS 4 , P ¼ 6.0 Â 10 À7 ) and in a hospital-based case-control study from Johns Hopkins Hospital (JHH 5 , P ¼ 5.1 Â 10 À4 ). To assess whether there were additional independent prostate cancer risk variants in the flanking region, we performed a fine-mapping analysis of the 17q12 genomic region in the CAPS and JHH study populations. This approach was motivated by the characterization of the 8q24 prostate cancer association, where at least two additional independent loci were subsequently discovered [6] [7] [8] [9] in the flanking region after the first locus at 8q24 was identified from a linkage-based association study 10 and an admixture mapping study 11 .
Our region of interest (33,111,655-33,189,279, build 35) for this fine-mapping effort spanned B80 kb and included the entire HNF1B gene and B10 kb upstream and downstream of the gene. A total of 41 tagging SNPs in the region of interest were identified on the basis of the HapMap Phase II data and genotyped using Sequenom iPLEX in CAPS (2,899 prostate cancer cases and 1,722 controls) and JHH (1,527 prostate cancer cases and 482 controls). A detailed description of the study subjects in these two populations is presented in Supplementary Methods and Supplementary Table 1 online. The average genotype call rate for these SNPs was 98.3%, and the average concordance rate was 99.8% among 100 duplicated quality control samples. All of the SNPs were in Hardy-Weinberg equilibrium (P Z 0.05) among each of the control groups. We also imputed 23 SNPs in the region using the computer program IMPUTE 12 . A posterior probability of 0.90 was used to call the imputed genotypes. We estimated pairwise linkage disequilibrium (LD) among these 64 SNPs in controls and inferred haplotype blocks using Haploview 13 . Heat maps for pairwise LD (D¢) of these SNPs in the entire finemapping region in CAPS and JHH are presented in Supplementary  Figure 1 online.
Allele-frequency differences between cases and controls in CAPS and JHH were tested for these 64 SNPs using a w 2 test with 1 degree of freedom (d.f.) (Supplementary Table 2 online). We also carried out a combined allelic test for CAPS and JHH study populations using the Cochran-Mantel-Haenszel test (Fig. 1a) . Two separate clusters of prostate cancer-associated SNPs were found; one was the previously identified region between 33,170,413 and 33,175,629 (first locus), including rs4430796, and the second was a newly identified region between 33,149,092 and 33,154,541 (second locus), B26 kb centromeric to the first locus. These two loci were in different haplotype blocks estimated from control subjects in CAPS and JHH using the Gabriel method 14 , and the two blocks were separated by five SNPs with low pairwise LD (Fig. 1b) . We also estimated the recombination rate between these two loci using 18 consecutive SNPs in the interval (bounded by rs4430796 at the first locus and rs11649743 at the second locus) among control subjects using SequenceLDhot software 15 . Strong evidence for a recombination hot spot between the two loci at 33,160,000-33,163,000 was found in JHH (P ¼ 1.2 Â 10 À15 ) and in CAPS (P ¼ 5.2 Â 10 À6 ) (Fig. 1c) . This is consistent with the known recombination hot spot at 33,162,001 in the HapMap data (Release 21, Phase I & II). These data strongly suggest that the two loci are genetically independent. The first locus spans a region between introns 1 and 2 of HNF1B, and the second locus resides within intron 4 ( Fig. 1d) .
To replicate the associations at these two loci, we used data from the publicly available National Cancer Institute Cancer Genetic Markers of Susceptibility (CGEMS) study. SNPs rs4430796 at locus 1 and rs11649743 at locus 2 were genotyped in five study populations of CGEMS, including PLCO, CPS-II, HPFS, FPCC and ATBC (Supplementary Methods) 6 . These two SNPs were selected to represent these two loci. Individual genotypes of PLCO were obtained through an approved application, and summary genotypes of the remaining four populations were downloaded from the public CGEMS website (http://cgems.cancer.gov/data/). The alleles at rs4430796 and rs11649743 that were associated with increased prostate cancer risk in CAPS and JHH were both higher in cases than controls in each of these five populations ( Table 1 ). The differences were statistically significant (P o 0.05) for four of the five populations for each SNP. We carried out combined allelic association tests among all seven study populations using a Cochran-Mantel-Haenszel test. Highly significant associations were found for rs4430796 (P ¼ 5.0 Â 10 À20 ) and for rs11649743 (P ¼ 1.7 Â 10 À9 ) among a total of 9,626 cases and 7,337 controls of European descent; both reached genome-wide significance level. We did not find any evidence for heterogeneity in allelic associations among these study populations using a Breslow-Day test for homogeneity (P ¼ 0.30 for rs4430796 and P ¼ 0.99 for rs11649743).
To infer the mode of inheritance of these two SNPs, we fit four genetic models in the combined data from CAPS, JHH and PLCO, where individual genotype data and age information are available, using a logistic regression analysis and adjusting for age (five-year group) and study population. These four models included a 2-d.f. general model and 1-d.f. additive, dominant and recessive models. The most parsimonious model, defined by lowest AIC value, was a recessive model for rs4430796 and an additive model for rs11649743 in the combined analysis (Supplementary Table 3 online). However, several other models had similar AIC values, reflecting a lack of statistical power to distinguish different genetic models in this analysis.
JHH + CAPS
We tested the independence of prostate cancer associations for these two SNPs by including both SNPs (assuming a general model at each SNP) in a logistic regression model in the combined data from CAPS, JHH and PLCO. The prostate cancer association at each SNP remained significant after adjustment for the other SNP, age (fiveyear group) and study population (Supplementary Table 4 online), suggesting that the prostate cancer associations at these two loci are independent. We then tested joint effects of these two SNPs on prostate cancer risk by estimating odds ratios (ORs) for prostate cancer for carriers of nine combined genotypes (unconstrained model) using a logistic regression model and adjusting for age and study. Using men who were homozygous for nonrisk alleles at both SNPs as a reference group, men who were homozygous for risk alleles at both SNPs had the highest risk in the combined study (OR ¼ 2.00, 95% CI ¼ 1.37-2.91; Supplementary Table 4) .
We inferred haplotypes for 18 consecutive SNPs bounded by rs4430796 at the first locus and rs11649743 at the second locus in the CAPS and JHH using PHASE (Supplementary Methods). More than 32 haplotypes with frequencies of 1% and higher were inferred, reflecting a recombination hot spot between the two loci (Supplementary Table 5 online). Three haplotypes that contain risk alleles of both rs4430796 and rs11649743 (ID: 1, 2 and 20) had higher frequencies in cases than controls (nominal P o 0.05); however, the results were not consistent in these two populations. These results suggested that the observed associations at the two independent loci are unlikely due to a single long-range haplotype that connects these two alleles.
These two SNPs were not associated with aggressiveness of prostate cancer in CAPS, JHH and PLCO (Supplementary Table 6 online). Although these two SNPs were associated with PSA levels in controls in CAPS, no associations were found in controls of JHH (Supplementary Table 6 ). Additional studies are needed to dissect associations of these SNPs with prostate cancer risk and PSA levels.
Although the frequency of the risk allele of rs4430796 was significantly higher in 364 cases (0.38) than 364 controls of African ancestry in JHH 5 (P ¼ 0.04), the frequency of the risk allele for rs11649743 was not significantly different between cases (0.934) and controls (0.935).
In summary, using data from our study populations and the publicly available data generated by CGEMS, we provide evidence of a second independent prostate cancer risk locus at 17q12. Notably, both these loci are located within HNF1B. Sequencing the exons of HNF1B in 200 men with prostate cancer revealed no mutations that could account for the original gene association observed in an Icelandic study population 1 . Additional studies will be necessary to uncover the causal mechanisms underlying the independent as well as possible interaction effects of these variants on prostate cancer risk.
Note: Supplementary information is available on the Nature Genetics website.
